https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-05-31 / J Clin Oncol 32:5s, 2014 (suppl; abstr 2087)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-05-31 / J Clin Oncol 32:5s, 2014 (suppl; abstr 2087)2014-05-31 11:58:292019-07-17 11:58:59Association of increased progression-free survival in primary glioblastomas with lymphopenia at baseline and activation of NK and NKT cells after dendritic cell immunotherapy.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-05-31 / J Clin Oncol 32:5s, 2014 (suppl; abstr 7583)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-05-31 / J Clin Oncol 32:5s, 2014 (suppl; abstr 7583)2014-05-31 00:00:002019-07-31 11:59:46Dendritic cell vaccination in malignant pleural mesothelioma: A phase I/II study.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-05-30 / J Clin Oncol 32, 2014 (suppl; abstr e15254)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-05-30 / J Clin Oncol 32, 2014 (suppl; abstr e15254)2014-05-30 00:00:002014-05-30 00:00:00A feasibility and safety study of vaccination with poly-ICLC and peptide-pulsed dendritic cells in patients with metastatic, locally advanced unresectable, or recurrent pancreatic adenocarcinoma.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-05-21 / Expert Rev Anticancer Ther 2014 Jul;14(7):761-3
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-05-21 / Expert Rev Anticancer Ther 2014 Jul;14(7):761-32014-05-21 00:00:002019-02-15 08:46:21Dendritic cell immunotherapy for glioblastoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-05-16 / Expert Opin Biol Ther 2014 Sep;14(9):1259-70
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-05-16 / Expert Opin Biol Ther 2014 Sep;14(9):1259-702014-05-16 00:00:002019-02-15 08:39:38Immunotherapy of cancer stem cells in solid tumors: initial findings and future prospective
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-05-13 / J Clin Biochem Nutr 2014 Jul;55(1):56-61
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-05-13 / J Clin Biochem Nutr 2014 Jul;55(1):56-612014-05-13 00:00:002019-02-15 09:17:12The inhibitory effect of heat treatment against epithelial-mesenchymal transition (EMT) in human pancreatic adenocarcinoma cell lines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-05-13 / J Immunother Cancer 2014;2:10
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-05-13 / J Immunother Cancer 2014;2:102014-05-13 00:00:002019-02-15 08:46:23Cytokine responsiveness of CD8(+) T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-05-13 / Cytotherapy 2014 Jul;16(7):946-64
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-05-13 / Cytotherapy 2014 Jul;16(7):946-642014-05-13 00:00:002021-11-15 13:30:25Development and validation of a fully GMP-compliant production process of autologous, tumor-lysate-pulsed dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-05-12 / Virol. J. 2014 May;11:84
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-05-12 / Virol. J. 2014 May;11:842014-05-12 00:00:002014-05-12 00:00:00Oncolytic therapy of a recombinant Newcastle disease virus D90 strain for lung cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-05-07 / J Ovarian Res 2014 May;7:48
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-05-07 / J Ovarian Res 2014 May;7:482014-05-07 00:00:002019-02-15 08:52:06The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer
